Sac-TMT for Active TNBC Brain Metastases

This is a multi-site prospective single-arm open-label phase 2 clinical trial including 20 participants with metastatic TNBC and active brain metastases to be treated with sacituzumab tirumotecan 4 mg/kg IV on Days 1, and 15 of every 28-day cycle until disease progression, unacceptable toxicities, consent withdrawal, or death.

NCT Number	NCT07458113
Lead Sponsor	Yale University Collaborators: Johns Hopkins University, Merck Sharp & Dohme LLC, Translational Breast Cancer Research Consortium
Conditions	Metastatic Triple Negative Breast Cancers
Enrollment	20 participants
Start Date	2026-08
Primary Completion	2028-08 (estimated)
Study Completion	2029-08 (estimated)
Updated on ClinicalTrials.gov	2026-07-24